Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent with a 8-year survival rate of ∼88%. Long-term toxicity of TKI treatment, especially carcinogenicity, has become a concern....

Descripción completa

Detalles Bibliográficos
Autores principales: Miranda, M B, Lauseker, M, Kraus, M-P, Proetel, U, Hanfstein, B, Fabarius, A, Baerlocher, G M, Heim, D, Hossfeld, D K, Kolb, H-J, Krause, S W, Nerl, C, Brümmendorf, T H, Verbeek, W, Fauser, A A, Prümmer, O, Neben, K, Hess, U, Mahlberg, R, Plöger, C, Flasshove, M, Rendenbach, B, Hofmann, W-K, Müller, M C, Pfirrmann, M, Hochhaus, A, Hasford, J, Hehlmann, R, Saußele, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895174/
https://www.ncbi.nlm.nih.gov/pubmed/26859076
http://dx.doi.org/10.1038/leu.2016.20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895174/
https://www.ncbi.nlm.nih.gov/pubmed/26859076
http://dx.doi.org/10.1038/leu.2016.20

Ejemplares similares